[Skip to Content]
[Skip to Content Landing]
Views 1,296
Citations 0
Viewpoint
June 26, 2019

The First Food and Drug Administration–Indicated Drug for Postpartum Depression—Brexanolone

Author Affiliations
  • 1Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 3Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Psychiatry. Published online June 26, 2019. doi:10.1001/jamapsychiatry.2019.1546

The burgeoning research on the short- and long-term adverse sequelae of perinatal depression on maternal, infant, and family health has prompted major medical and public health agencies to urge identification and treatment. Deaths due to psychiatric illness and drug overdose lead the causes of maternal mortality in the first year after birth.1 Finding novel treatments with improved effectiveness for depression in postpartum women is a pressing public health goal.

×